HPCGG: Partnerships

In February of 2005, Harvard Partners Center for Genetics and Genomics (HPCGG) and Affymetrix, Inc. (Nasdaq: AFFX) announced an agreement that will provide HPCGG with early access to next-generation Affymetrix GeneChip Human Mapping microarrays capable of scanning up to 500,000 Single Nucleotide Polymorphisms (SNPs), or variations of DNA sequence in the human genome. The Affymetrix technology will allow HPCGG researchers to investigate at an unprecedented scale the genetic origins of atherosclerosis, a condition where the arteries become clogged. More than 1200 patient samples will be examined and will come from the Women's Health Study, an ongoing 10-year National Institutes of Health (NIH) funded study of cardiovascular events in 38,000 women.

In April of 2004 Partners HealthCare and Agilent Technologies announced a one-year agreement under which Agilent will provide microarray and gene expression products to the Partners hospitals.

In August of 2003, Partners HealthCare and Guava Technologies entered into a two-year alliance centered on Guava’s proprietary cell-analysis platform, the PCA (Personal Cell Analysis). This relationship is designed to provide PHS scientists with exposure to this new technology and to develop novel applications for the platform that will be of use to the research community. Partners access to this technology will be achieved through a rotating series of PCA-based research projects being conducted by PHS investigators. During the course of this relationship, PHS scientists will have an opportunity to purchase Guava products at a preferential rate.

In September 2003, Partners HealthCare (PHS) entered into a corporate sponsorship agreement with Hewlett-Packard (HP), a leading global provider of products, technologies, solutions and services, to develop a genomic and genetic computing platform and infrastructure to support research and clinical activities at Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) and within the broader research communities across PHS. PHS and HP have established a partnership, whereby both organizations will combine their collective expertise, domain knowledge, experience, and technology to deliver on specific clinical genomics solutions.

A five-year alliance that provides a facilitated pathway for Millennium sponsored basic and clinical research through:

Access to Millennium proprietary process and key technologies through facilitated sponsored research
Development and commercialization of inventions made during the course of research
Licensing of technology from PHS to Millennium
Transfer of genetic and other biologic materials within sponsored research collaborations

Click here for more information.

An alliance that marks the establishment of a functional proteomics core at the Harvard - Partners Center for Genetics and Genomics to support protein research endeavors across the PHS Hospitals.

A three-year sponsored research alliance achieving the following objectives: 1.) to provide PHS scientists access to the Zyomyx Protein Biochip System and protein chip technology for advancing their research 2.) to provide PHS with sponsored research opportunities, and 3.) to assist Zyomyx in validating its protein Biochips.